Source Count: 10 | Weighted Score: 26 | Source Confidence: [3/5] | Primary Tier: 1 | Last Updated: March 11, 2026
Keywords: neurology, nervous system, brain, stroke, epilepsy, Alzheimer, Parkinson, multiple sclerosis, Charcot, neuroimaging, neurodegenerative, headache, neuropathy, EEG, MRI
Category Tags: medicine-healing, neurology, brain, neurodegenerative-disease
Cross-References: K_1_01 — Consciousness Overview · X_2_13 — Pain Science · X_3_06 — Radiology and Medical Imaging

QUICK SUMMARY

Neurology is the branch of medicine dealing with disorders of the nervous system — the brain, spinal cord, peripheral nerves, and neuromuscular junction. The discipline encompasses some of the most devastating and challenging conditions in medicine: stroke (the second leading cause of death globally and a leading cause of disability), epilepsy (~50 million people worldwide), Alzheimer's disease (~55 million worldwide with dementia, of which Alzheimer's accounts for 60–70%), Parkinson's disease (~10 million), multiple sclerosis (~2.8 million), and headache disorders (migraine alone affects ~1 billion people). The modern specialty was founded by Jean-Martin Charcot (1825–1893) at the Salpêtrière Hospital in Paris — who systematically described multiple sclerosis, amyotrophic lateral sclerosis (ALS, also known as Charcot's disease in France), and many other neurological conditions using the clinico-anatomical method (correlating clinical symptoms with pathological findings at autopsy). Neurology has been transformed by neuroimaging — CT scanning (1971), MRI (1980s), functional MRI, PET scanning — which enabled the non-invasive visualization of the living brain; by electrophysiology (EEG — Hans Berger, 1929; nerve conduction studies; electromyography); and by therapeutic advances including stroke thrombolysis and thrombectomy, disease-modifying therapies for multiple sclerosis, deep brain stimulation for Parkinson's disease, and monoclonal antibodies for migraine prevention. Yet neurology retains the challenge that many of its most prevalent conditions — Alzheimer's disease, ALS, many epilepsies — remain without curative treatment.

1. VERIFIED CLAIMS (Tier 1 — Peer-Reviewed / Established)

1.1 Historical Foundations

• Jean-Martin Charcot (1825–1893): professor of diseases of the nervous system at the Salpêtrière Hospital, Paris; systematically described multiple sclerosis (1868 — identifying the clinical triad and pathological features), amyotrophic lateral sclerosis (ALS/motor neuron disease — Charcot's disease), and Charcot-Marie-Tooth disease; developed the clinico-anatomical method (correlating neurological symptoms with post-mortem pathology) as the foundation of neurological diagnosis
• Santiago Ramón y Cajal (1852–1934): established the neuron doctrine — that the nervous system is composed of discrete cells (neurons) rather than a continuous network (the rival "reticular theory" of Camillo Golgi); Nobel Prize in Physiology or Medicine, 1906 (shared with Golgi)
• Alois Alzheimer (1864–1915): described the clinical and pathological features of Alzheimer's disease (1906) — including neurofibrillary tangles and amyloid plaques in the brain of a patient (Auguste Deter) with progressive dementia
• Hans Berger (1873–1941): performed the first human electroencephalogram (EEG) recording (1929) — demonstrating that electrical activity of the brain could be measured non-invasively; identified alpha and beta rhythms

1.2 Stroke

• Stroke (cerebrovascular accident): the sudden interruption of blood supply to the brain — either by occlusion (ischemic stroke — ~87% of all strokes) or hemorrhage (hemorrhagic stroke — ~13%)
• Thrombolysis: intravenous tissue plasminogen activator (tPA/alteplase) — the first effective acute treatment for ischemic stroke (NINDS trial, 1995); must be administered within 4.5 hours of symptom onset
• Mechanical thrombectomy: endovascular removal of large-vessel occlusion clots using stent retrievers or aspiration devices; demonstrated dramatic benefit in multiple randomized trials (MR CLEAN, 2015, and subsequent trials); effective up to 24 hours in selected patients with salvageable brain tissue; one of the most important advances in neurology in decades

1.3 Epilepsy

• Epilepsy: a neurological disorder characterized by recurrent, unprovoked seizures — affecting ~50 million people worldwide; treated with antiseizure medications (phenobarbital, 1912; phenytoin, 1938; newer agents including levetiracetam, lacosamide), and in drug-resistant cases, epilepsy surgery (surgical resection of the seizure focus — effective in ~60–80% of selected temporal lobe epilepsy cases)
• John Hughlings Jackson (1835–1911): proposed that epilepsy results from excessive, disorderly discharge of neurons — a remarkably prescient formulation confirmed by modern electrophysiology

2. CREDIBLE CLAIMS (Tier 2 — Academic / Debated but Supported)

2.1 Neurodegenerative Diseases

• Alzheimer's disease: the most common cause of dementia; characterized by accumulation of amyloid-beta plaques and tau neurofibrillary tangles; the amyloid hypothesis (that Aβ accumulation is the primary driver of disease) has dominated research for decades but is increasingly debated — anti-amyloid antibodies (aducanumab — controversial FDA approval 2021; lecanemab — FDA-approved 2023) reduce amyloid plaques but show only modest clinical benefit
• Parkinson's disease: progressive neurodegenerative disorder characterized by loss of dopaminergic neurons in the substantia nigra → tremor, rigidity, bradykinesia; treated with levodopa (the most effective symptomatic treatment — since 1967), dopamine agonists, MAO-B inhibitors; deep brain stimulation (DBS) of the subthalamic nucleus — approved treatment for motor fluctuations in advanced Parkinson's
• Multiple sclerosis (MS): autoimmune demyelinating disease of the central nervous system; ~2.8 million people affected; over 20 disease-modifying therapies (DMTs) now available — from injectable interferons (1993) to high-efficacy oral and infusion therapies (ocrelizumab, ofatumumab, cladribine); treatment has transformed the prognosis of MS from a progressively disabling condition to one where many patients maintain near-normal function

2.2 Neuroimaging Revolution

• CT scanning (Godfrey Hounsfield and Allan Cormack — Nobel Prize, 1979): first clinical brain CT (1971) — revolutionized the diagnosis of stroke, tumors, and hemorrhage
• MRI: provides high-resolution structural imaging of the brain without radiation — essential for diagnosing MS, tumors, dementia, and many other conditions
• Functional MRI (fMRI): measures brain activity via blood-oxygen-level-dependent (BOLD) signal — used in presurgical mapping and neuroscience research
• Neuroimaging transformed neurology from a primarily diagnostic specialty (identify the lesion, but often unable to treat) to a field where imaging guides acute intervention (thrombectomy for stroke, surgical planning for tumors and epilepsy)

3. SPECULATIVE CLAIMS (Tier 3 — Possible but Unverified)

3.1 Disease-Modifying Treatment for Alzheimer's

• Whether amyloid-targeting therapies will ultimately produce meaningful clinical benefit for Alzheimer's patients remains uncertain — lecanemab showed statistically significant but clinically modest slowing of cognitive decline (27% slowing over 18 months) with risks including cerebral edema and microhemorrhages; the field is actively debating whether Alzheimer's requires fundamentally different therapeutic approaches (targeting tau, neuroinflammation, or metabolic pathways)

4. DUBIOUS CLAIMS (Tier 4 — No Credible Source / Contradicted by Evidence)

4.1 "We Only Use 10% of Our Brain"

• [REFUTED] The popular myth that humans only use 10% of their brain — neuroimaging and neurological clinical evidence demonstrate that the entire brain is active and functionally significant; lesions in virtually any brain region produce detectable neurological deficits

Counter-Arguments & Criticisms

No significant counter-arguments exist in the scholarly literature for the core claims in this document. Neurology: The Clinical Science of the Nervous System represents established medical science consensus with no active scholarly dispute over the fundamental claims presented here.

IMAGES

No images assigned yet.

BIBLIOGRAPHY

1. Ropper, Allan H.; Martin A | 2019 | ∅ | Adams and Victor's Principles of Neurology | ∅ | ∅ | Samuels | 11th | doi:10.1002/ana.410270422 | ∅ | ∅ | New York: McGraw-Hill
2. Goetz, Christopher G | 1998 | "Charcot, the Clinician: The Tuesday Lessons" | Annals of Neurology | ∅ | 43.1::133–135 | ∅ | ∅ | doi:10.1002/ana.410240622 | ∅ | ∅ | ∅
3. National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group (corp.) | 1995 | "Tissue Plasminogen Activator for Acute Ischemic Stroke" | New England Journal of Medicine | ∅ | 333.24::1581–1587 | ∅ | ∅ | doi:10.1056/nejm199512143332401 | ∅ | ∅ | ∅
4. Berkhemer, Olvert A., et al. (MR CLEAN) | 2015 | "A Randomized Trial of Intraarterial Treatment for Acute Ischemic Stroke" | New England Journal of Medicine | ∅ | 372.1::11–20 | ∅ | ∅ | doi:10.1056/nejmx140064 | ∅ | ∅ | ∅
5. Alzheimer, Alois | 1907 | "Über eine Eigenartige Erkrankung der Hirnrinde" | Allgemeine Zeitschrift für Psychiatrie | ∅ | 64::146–148 | ∅ | ∅ | doi:10.1007/bf02867019 | ∅ | ∅ | ∅
6. van Dyck, Christopher H., et al | 2023 | "Lecanemab in Early Alzheimer's Disease" | New England Journal of Medicine | ∅ | 388.1::9–21 | ∅ | ∅ | ∅ | ∅ | ∅ | ∅
7. Deuschl, Günther, et al | 2006 | "A Randomized Trial of Deep-Brain Stimulation for Parkinson's Disease" | New England Journal of Medicine | ∅ | 355.9::896–908 | ∅ | ∅ | ∅ | ∅ | ∅ | ∅
8. Thompson, Alan J., et al | 2018 | "Multiple Sclerosis" | The Lancet | ∅ | ∅ | 391.10130 : 1622 1636 | ∅ | ∅ | ∅ | ∅ | ∅
9. Ramón y Cajal, Santiago | 1995 | ∅ | Histology of the Nervous System of Man and Vertebrates | ∅ | ∅ | Translated by Neely Swanson and Larry W | ∅ | ∅ | ∅ | ∅ | Swanson; Oxford: Oxford University Press, [1899]
10. Fisher, Robert S., et al | 2014 | "ILAE Official Report: A Practical Clinical Definition of Epilepsy" | Epilepsia | ∅ | 55.4::475–482 | ∅ | ∅ | ∅ | ∅ | ∅ | ∅

CROSS-REFERENCE INDEX

Generated from V4 expansion plan. Last Updated: March 11, 2026